High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: A systematic review with meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 1, 2014, Pages 1-10

  Rancea, Michaela ^a   von Tresckow, Bastian ^a   Monsef, Ina ^a   Engert, Andreas ^a   Skoetz, Nicole ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Hodgkin lymphoma; Meta analysis; Relapse; Treatment

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HODGKIN DISEASE; HUMAN; META ANALYSIS; MORTALITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84906933742     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.04.003     Document Type: Review

References (24)

1. Krebs in Deutschland 2007/2008 2012, Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg), Berlin.
2. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011, 117(16):4208-4217.
3. Skoetz N., Trelle S., Rancea M., et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013, 14(10):943-952.
4. Thomas R.K., Re D., Zander T., Wolf J., Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Ann Oncol 2002, 13(Suppl. 4):147-152.
5. Swerdlow A.J. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003, 30(Suppl. 1):S3-S12.
6. Josting A., Muller H., Borchmann P., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010, 28(34):5074-5080.
7. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341(8852):1051-1054.
8. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359(9323):2065-2071.
9. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002, 20(1):221-230.
10. Lefebvre C., Manheimer E., Glanville J. Chapter 6: searching for studies. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011): The Cochrane Collaboration 2011, J.P.T. Higgins, S. Green (Eds.).
11. Higgins J.P.T., Deeks J.J. Chapter 7: selecting studies and collecting data. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011): The Cochrane Collaboration 2011, J.P.T. Higgins, S. Green (Eds.).
12. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62(10):1006-1012.
13. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834.
14. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
15. Deeks J.J., Higgins J.P.T., Altman D.G. Chapter 9: analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011): The Cochrane Collaboration 2011, J.P.T. Higgins, S. Green (Eds.).
16. Higgins J.P.T., Altman D.G. Chapter 8: assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011): The Cochrane Collaboration 2011, J.P.T. Higgins, S. Green (Eds.).
17. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration 2011, J.P.T. Higgins, S. Green (Eds.).
18. Morschhauser F., Brice P., Ferme C., et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008, 26(36):5980-5987.
19. Josting A., Rudolph C., Reiser M., et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002, 13(10):1628-1635.
20. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97(3):616-623.
21. Santoro A., Magagnoli M., Spina M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007, 92(1):35-41.
22. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363(19):1812-1821.
23. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30(18):2183-2189.
24. Moskowitz A.J., Hamlin P.A., Perales M.-A., et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013, 31(4):456-460.